Talk:COVID-19 drug development
This is the talk page for discussing improvements to the COVID-19 drug development article. This is not a forum for general discussion of the article's subject. |
Article policies
|
Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL |
Archives: 1Auto-archiving period: 14 days ![]() |
![]() | This article is rated B-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
![]() | WikiProject COVID-19 consensus WikiProject COVID-19 aims to add to and build consensus for pages relating to COVID-19. They have so far discussed items listed below. Please discuss proposed improvements to them at the project talk page.
To ensure you are viewing the current list, you may wish to . |
![]() | The contents of the COVID-19 drug repurposing research page were merged into COVID-19 drug development on 7 April 2020. For the contribution history and old versions of the redirected page, please see its history; for the discussion at that location, see its talk page. |
![]() | Material from COVID-19 drug development was split to Bamlanivimab on 10 December 2020. The former page's history now serves to provide attribution for that content in the latter page, and it must not be deleted so long as the latter page exists. Please leave this template in place to link the article histories and preserve this attribution. |
![]() | Daily pageviews of this article
A graph should have been displayed here but graphs are temporarily disabled. Until they are enabled again, visit the interactive graph at pageviews.wmcloud.org |
![]() | The contentious topics procedure applies to this page. This page is related to COVID-19, broadly construed, which has been designated as a contentious topic. Editors who repeatedly or seriously fail to adhere to the purpose of Wikipedia, any expected standards of behaviour, or any normal editorial process may be blocked or restricted by an administrator. Editors are advised to familiarise themselves with the contentious topics procedures before editing this page. |
Include interferon lambda in the list of drugs being tested for COVID.
[edit]Multiple clinical trials are investigating the use of Interferon Lambda to treat COVID.[1][2][3]
References
Add sabizabulin
[edit]Sabizabulin "halved the death rate among critically ill Covid patients who were receiving supplemental oxygen and were at high risk for serious lung disease and death"
New Drug Slashed Deaths Among Patients With Severe Covid, Maker Claims https://www.nytimes.com/2022/04/11/health/covid-sabizabulin-veru.html
National Center for Biotechnology Information (2022). PubChem Compound Summary for CID 53379371, Sabizabulin. Retrieved April 12, 2022 from https://pubchem.ncbi.nlm.nih.gov/compound/Sabizabulin
Sabizabulin (VERU-111) for COVID-19 https://verupharma.com/pipeline/sabizabulin-for-covid-19/
Veru’s Novel COVID-19 Drug Candidate Reduces Deaths by 55% in Hospitalized Patients in Interim Analysis of Phase 3 Study; Independent Data Monitoring Committee Halts Study Early for Overwhelming Efficacy https://www.globenewswire.com/news-release/2022/04/11/2419839/11676/en/Veru-s-Novel-COVID-19-Drug-Candidate-Reduces-Deaths-by-55-in-Hospitalized-Patients-in-Interim-Analysis-of-Phase-3-Study-Independent-Data-Monitoring-Committee-Halts-Study-Early-for-.html
2600:1000:B00F:64AC:D8E9:99AA:2866:936 (talk) 13:50, 12 April 2022 (UTC)
- Thanks for posting this. We would not use the press releases as reliable sources for this information, so need to wait for peer reviewed articles or independent newspaper reports before including the supposed efficacy. In addition, this might be more suitable for this article - COVID-19 drug repurposing research - as the drug was in development already for cancer. Either way, I expect there will be more information published soon and if the press report is borne out then it should be included.
- Currently, one review lists the trial in a table , and it has a listing on ClinicalTrials.gov. |→ Spaully ~talk~ 14:14, 12 April 2022 (UTC)
Semi-protected edit request on 28 July 2023
[edit]![]() | This edit request has been answered. Set the |answered= or |ans= parameter to no to reactivate your request. |
Specia = Special 2603:8000:D300:D0F:2098:B4E2:5069:2E94 (talk) 04:55, 28 July 2023 (UTC)
Not done: That appears to be a person's last name, located in a reference to this article which lists Megan Specia as an author. Tollens (talk) 05:13, 28 July 2023 (UTC)
- B-Class COVID-19 articles
- High-importance COVID-19 articles
- Wikipedia requested images of COVID-19-related topics
- WikiProject COVID-19 articles
- B-Class medicine articles
- Mid-importance medicine articles
- B-Class pulmonology articles
- Mid-importance pulmonology articles
- Pulmonology task force articles
- Wikipedia requested images of medical subjects
- All WikiProject Medicine pages
- B-Class pharmacology articles
- Mid-importance pharmacology articles
- WikiProject Pharmacology articles
- B-Class virus articles
- Mid-importance virus articles
- Wikipedia requested images of viruses
- WikiProject Viruses articles
- B-Class Disaster management articles
- Mid-importance Disaster management articles
- B-Class International relations articles
- Mid-importance International relations articles
- WikiProject International relations articles